Quantum Biopharma expects data from two now-completed, FDA-requested toxicology studies to support clinical testing of its ...

The company recently hit significant roadblocks with its BTK inhibitor, but there are plenty of fish in the sea for the drug ...

The festive period brought some unwanted post for both Sanofi and Corcept Therapeutics in the form of FDA rejections for the ...

The FDA approved Scinopharm's glatiramer acetate injection, a generic version of Copaxone, to treat multiple sclerosis.

Less than two weeks after rejecting Sanofi’s investigational multiple sclerosis drug, the FDA has publicly shared the ...

Last month, the FDA declined to approve Sanofi’s tolebrutinib for a specific form of multiple sclerosis. In a recently ...

Women under age 40 with multiple sclerosis are 8 percent less likely than men to receive disease-modifying drugs, a new study has found. Uncertainty about the impact of these drugs during pregnancy ...

NICE has recommended natalizumab for adults with highly active RRMS, citing pregnancy suitability, biosimilar value and NHS ...

RIVERSIDE, N.J. (WPVI) -- A multiple sclerosis diagnosis used to mean a future of disability. But now, a revolution in medications allows MS patients to pursue their dreams. Those medications are ...

An analysis of over 3,700 pregnancies of women with multiple sclerosis indicates that the therapy doesn’t lead to increased risks of miscarriage, premature birth or serious birth defects. Many women ...

MS patients with Medicare plans that exclude more drugs have a higher risk of relapse They might not be able to afford the drugs that would work best for them TUESDAY, Aug. 5, 2025 (HealthDay News) — ...

Even women with more severe MS cases are less likely than men to get critical treatments, a new study finds. Women under age 40 with multiple sclerosis are 8 percent less likely than men to receive ...